In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project by Judson, Richard S. et al.
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 4 | April 2010  485
Research
There are thousands of environmental chemi-
cals, including many industrial chemicals and 
pesticidal active and inert ingredients, with 
the potential for significant human exposures 
but for which toxicity information is either 
limited or nonexistent (Judson et al. 2009). 
This data gap is due largely to the high cost 
and length of time required to conduct ani-
mal testing in rodents and other species. A 
complete set of regulatory tests for a single 
chemical (including those for carcinogenic-
ity and for chronic, reproductive, and devel-
opment toxicity) uses thousands of animals 
and costs millions of dollars. In addition, 
traditional animal tests often yield limited 
information on mechanism of action, and 
hence on the cellular pathways that could 
lead to toxicity in humans. Such mechanistic 
information is key to moving beyond default 
approaches for extrapolating from high-dose 
animal toxicity tests to estimation of human 
risk at realistic exposure levels.
There is a pressing need to screen the 
large backlog of chemicals for their potential 
toxicity and, ultimately, their contribution 
to human diseases. The National Research 
Council (2007) advocated the use of mecha-
nistically informative in vitro assays based on 
human cells or human cell constituents that 
measure effects on “toxicity pathways” leading 
to human disease. The U.S. Environmental 
Protection Agency (EPA), through its 
ToxCast program (Dix et al. 2007) and 
the Tox21 collaboration with the National 
Toxicology Program and the National 
Institutes of Health Chemical Genomics 
Center, is pursuing similar objectives and 
applying many of the ideas represented in the 
National Research Council report (Collins 
et al. 2008; Kavlock et al. 2009).
ToxCast is a large-scale experiment using 
a battery of in vitro, high-throughput screen-
ing (HTS) assays, applied to a relatively large 
and diverse chemical space, to develop meth-
ods to predict potential toxicity of environ-
mental chemicals at a fraction of the cost of 
full-scale animal testing. Three major goals of 
ToxCast are to a) identify in vitro assays that 
can reliably indicate alterations in biologi-
cal processes of relevance to in vivo toxicity; 
b) develop signatures or prediction models 
based on multiple assays, along with com-
puted or available chemical properties, that 
can achieve higher predictive power than 
single assays or chemical structure alone; and 
c) use these combined in silico and in vitro 
assay-based signatures to screen large numbers 
of previously untested environmental chemi-
cals. The ToxCast data set provides a rich 
resource for identifying chemically induced 
changes in biological pathways that are associ-
ated with in vivo end points and that could 
potentially lead to human disease. Chemicals 
whose properties and assay profiles match 
these predictive signatures can be prioritized 
for more in-depth testing, which may include 
nontraditional, mechanism-focused in vivo 
tests. In this article, we provide an overview of 
the entire ToxCast phase I assay results data 
set and present initial analyses and findings.
Materials and Methods
Phase I of ToxCast employed a chemical 
library of 320 substances (U.S. EPA 2008a). 
Within this set there are 309 unique chemi-
cals, most of which are food-use pesticides 
for which extensive animal testing results are 
available. The mechanisms of toxicity for a 
number of these chemicals are known, thus 
affording the opportunity to match in vitro 
results with existing knowledge. Further 
information on the chemical library is pro-
vided in the Supplemental Material (available 
online at doi:10.1289/ehp.0901392).
We screened the chemical library using 
nine separate assay technologies, with assays 
run in concentration–response format and in 
some cases with multiple time points. Assays 
encompass both direct, primary interac-
tions between chemicals and molecular tar-
gets and downstream cellular events such as 
gene expression. Table 1 summarizes the nine 
in vitro assay technologies, and Supplemental 
Material, Table 1 (doi:10.1289/ehp.0901392) 
lists the complete set of in vitro assays. There 
are 467 cell-free or cell-based assays. Assay sets 
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Ba c k g r o u n d: Chemical toxicity testing is being transformed by advances in biology and computer 
modeling, concerns over animal use, and the thousands of environmental chemicals lacking toxicity 
data. The U.S. Environmental Protection Agency’s ToxCast program aims to address these con-
cerns by screening and prioritizing chemicals for potential human toxicity using in vitro assays and 
in silico approaches.
oBjectives: This project aims to evaluate the use of in vitro assays for understanding the types of 
molecular and pathway perturbations caused by environmental chemicals and to build initial priori-
tization models of in vivo toxicity.
Me t h o d s : We tested 309 mostly pesticide active chemicals in 467 assays across nine technologies, 
including high-throughput cell-free assays and cell-based assays, in multiple human primary cells 
and cell lines plus rat primary hepatocytes. Both individual and composite scores for effects on 
genes and pathways were analyzed.
re s u l t s: Chemicals displayed a broad spectrum of activity at the molecular and pathway levels. We 
saw many expected interactions, including endocrine and xenobiotic metabolism enzyme activity. 
Chemicals ranged in promiscuity across pathways, from no activity to affecting dozens of pathways. 
We found a statistically significant inverse association between the number of pathways perturbed 
by a chemical at low in vitro concentrations and the lowest in vivo dose at which a chemical causes 
toxicity. We also found associations between a small set of in vitro assays and rodent liver lesion 
formation.
co n c l u s i o n s: This approach promises to provide meaningful data on the thousands of untested 
environmental chemicals and to guide targeted testing of environmental contaminants.
key w o r d s : in vitro screening, liver proliferative lesions, liver tumors, pathways, ToxCast. Environ 
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include biochemical HTS and cell-based HTS 
assays measuring direct molecular interactions 
with specific protein targets; high-content cell-
imaging assays measuring complex cellular 
phenotypes; a multiplexed gene expression 
assay for xenobiotic metabolizing enzymes 
and transporters in human primary hepato-
cytes; multiplexed transcription factor reporter 
assays; multiplexed biological activity profiling 
assays measuring biomarkers in a variety of 
human primary cell cocultures; assays measur-
ing effects of phase I and II xenobiotic metab-
olizing enzyme (XMEs) on cytotoxicity; an 
HTS genotoxicity assay; and a real-time cellu-
lar impedance assay that measures the kinetics 
of cell growth and changes in morphology. For 
all cell-based assays, time points were selected 
on the basis of studies conducted during the 
assay development and were considered opti-
mal for the end point being evaluated.
A total of 624 in vitro assay end points 
(including multiple time points) were meas-
ured for each chemical, generating > 200,000 
concentration responses. Assays have been 
mapped to a total of 315 genes, most of which 
are human (231) or rat (65) [see Supplemental 
Material, Table 1 (doi:10.1289/ehp.0901392)]. 
In all cases we report a charac  teristic micro-
molar concentration for each chemical–assay 
combination. These values were either half-
maximal activity concentration (AC50) or 
lowest effective concentration (LEC) at which 
there was a statistically significant change from 
the concurrent negative control. Criteria for 
determining the characteristic concentration is 
given in the Supplemental Material. Chemical–
assay combinations that did not show signifi-
cant activity below the highest concentration 
tested were labeled inactive. The complete 
data set, including AC50/LEC values for all 
chemical–assay measurement pairs, is available 
from the EPA ToxCast Web site (U.S. EPA 
2008b). Experimental protocols and informa-
tion on data quality are summarized in the 
Supplemental Material.
Many of the compounds in our library 
have matching guideline study animal toxicity 
data. Information from regulatory toxicity 
studies on the pesticide compounds submit-
ted to the U.S. EPA (Knudsen et al. 2009; 
Martin et al. 2009a, 2009b) were compiled 
in the U.S. EPA Toxicity Reference Database 
(ToxRefDB) (U.S. EPA 2008c). Study types 
include rat and mouse 2-year cancer or chronic 
bioassays, rat multigenerational reproductive 
toxicity assays, and rat and rabbit prenatal 
developmental toxicity assays. ToxRefDB pro-
vides the lowest effective level at which par-
ticular in vivo treatment-related effects were 
significantly different from negative controls. 
For each of the in vivo study types, typically 
250–280 of the ToxCast chemicals had data 
available and entered into ToxRefDB.
Results
Figure 1 shows a heat map of the entire 
in vitro data set, providing an overview of the 
data. Generally, the biochemical HTS assays 
(indicated by red in the top band) had fewer 
hits than did the cell-based assays, as evident 
from the increasing density of hits progress-
ing from left to right in the heat map. On 
the left side of this plot are 87 assays that had 
no AC50/LEC values identified for any of the 
chemicals at levels below the highest concen-
tration tested (see Table 1 for concentration 
ranges tested). In Figure 1, all hits are shown, 
up to where the AC50/LEC occurred at the 
highest tested concentration. However, some 
of these values may not be physiologically rele-
vant because in vitro systems can be exposed to 
concentrations higher than can occur in vivo in 
relevant tissues under conditions of a bioassay. 
Supplemental Material, Figure 1 (doi:10.1289/
ehp.0901392) shows the number of hits 
per chemical as a function of the threshold 
AC50/LEC values used to define a hit. At the 
comparatively low threshold of 1 µM, there 
were relatively few hits per chemical. There 
were 828 chemical–assay pairs (0.5% of pairs 
tested) with an AC50/LEC < 1 µM (listed in 
Supplemental Table 2), many of which were 
related to nuclear-  receptor–mediated xeno-
biotic metabolism. Of the chemicals that had 
AC50/LEC values < 1 µM in multiple assays, 
some showed cytotoxicity in one or more of 
the cell-based assays, which suggests cytotox-
icity pathway activation, although in many 
cases we do not have a specific (cell-free) assay 
that would indicate which pathway that was. 
Cytotoxicity may comprise a relevant end 
point of specific biological process(es) lead-
ing to cellular demise (e.g., apoptosis), or it 
may comprise nonspecific collapse of cellular 
homeostasis (e.g., necrosis). Both are consid-
ered in phase I, and the former may be the 
result of targeted pathways engaged by specific 
molecular lesions, whereas the latter may gen-
erally follow from nonspecific cell injury. In 
other chemicals, we only saw specific targeted 
activities at these low concentrations, without 
any accompanying cytotoxicity.
Confidence in the predictive power of 
in vitro HTS data builds from many exam-
ples that confirm reported mechanisms of 
action for a number of well-studied chemi-
cals. For example, bisphenol A, a known 
estrogen receptor (ER) agonist (Chapin et al. 
2008), had AC50/LEC values < 1 µM for 
three separate ER (estrogen receptor, ESR1) 
assays [Supplemental Material, Table 2 
(doi:10.1289/ehp.0901392)]. Expected ER 
activity at concentrations < 1 µM was also 
found for methoxychlor’s potent metabolite 
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloro-
ethane. Similarly, results for the well-known 
androgen receptor (AR) antagonists linuron, 
prochloraz, and vinclozolin (Wilson et al. 
2008) showed activity in AR assays (linuron, 
57 µM antagonist, 5.1 µM binding; prochlo-
raz, 12.5 µM binding; vinclozolin, 27 µM 
antagonist, 0.9 µM binding). Expected peroxi-
some proliferator–activated receptor (PPAR) 
activators perfluorooctanoic acid (PFOA) 
and perfluorooctane sulfonic acid (PFOS) 
(DeWitt et al. 2009; Lau et al. 2004), di  ethyl-
hexyl phthalate (Melnick 2001), and lactofen 
(Butler et al. 1988) were all positive for PPARγ 
assays, and all but PFOS were also active in 
PPARα assays. Azoxystrobin, fluoxastrobin, 
and pyraclostrobin were active mitochondrial 
Table 1. Summary of the ToxCast in vitro assays: types of cells, number of concentrations (concentration range), time points, and types of readout. 
Assay set Assays Cell type Concentrations (µM) Time points Readout
Cell-free HTS 239 Cell free CYP assays: 8 (0.00914–20)
All others: 8 (0.0229–50)
1 IC50
Cell-based HTS 13 HEK293, HeLa, HepG2, FAO 15 (0.0012–92) 1 IC50
High-content cell imaging 19 HepG2 and primary rat hepatocytes 10 (0.39–200) 3 (1, 24, 72 hr) IC50
Quantitative Nuclease protection 16 Primary human hepatocytes 5 (0.004–40) 3 (6, 24, 48 hr) IC50
Multiplex transcription reporter 81 HepG2 7 (0.0014–100) 1 LEC
Biologically multiplexed activity 
profiling (BioMAP)
87 HUVEC, HDFn, HBEC, ASMC,  
KC, PBMC
4 (1.48–40) 1 LEC (separate up- and  
down-regulation readouts)
Phase I and II XME cytotoxicity 4 Hep3B 9 (0.0146–960) 1 IC50
HTS genotoxicity 1 TK6 3 (50–200) 1 LEC
Real-time cell electronic sensing 7 A549 8 (0.047–100) Continuous (0–48 hr) IC50, LEC
Abbreviations: A549, human alveolar basal epithelial cell carcinoma cell line 549; ASMC, arterial smooth muscle cells; CYP, cytochrome P450; FAO, Reuber rat hepatoma cell line; HBEC, 
human bronchial epithelial cells; HDFn, human neonatal foreskin fibroblasts; HEK293, Human embryonic kidney cell line 293; HeLa, Henrietta Lacks cervical cancer cell line; Hep3B, hepa-
tocellular carcinoma cell line 3b; HepG2, hepatocellular carcinoma cell line G2; HUVEC, human umbilical vein endothelial cells; KC, keratinocytes; PBMC, peripheral blood mononuclear 
cells; TK6, T-cell blast cell line 6. Data were collected in concentration–response format for each chemical–assay pair. If data were fit to a Hill function, we report the AC50 values. In 
other cases, an LEC was determined by significant change relative to negative control. Assay methods are described in more detail in Supplemental Material (doi:10.1289/ehp.0901392). ToxCast: in vitro screening of environmental chemicals
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poisons in the HepG2 (hepatocellular carci-
noma cell line G2) high-content cell-imaging 
assays, consistent with their pesticidal mode of 
action (Brandt et al. 1988). Thus, the redun-
dancy and complementarity of multiple assays 
allow an integration of data across multiple 
assay technologies to boost confidence in the 
results. In some cases, in vitro results include 
indications of other biological pathways being 
activated by these well-studied chemicals, sug-
gesting that other modes of action may be 
operative as well. To take one chemical as an 
example, PFOS shows activity against several 
matrix metalloproteinases, with AC50 values 
for direct interaction with matrix metallo-
proteinase (MMP)3 and MMP13 in cell-free 
HTS assays (14.6 and 32.4 µM, respectively) 
and perturbation of MMP1 and MMP9 levels 
in a cell-based assay (13.3 and 4.4 µM, respec-
tively). MMPs are involved in the breakdown 
of extracellular matrix during development 
and tissue remodeling. These and other inter-
actions could lead to the formation of specific 
hypotheses to test regarding toxicity mecha-
nisms of these chemicals.
Activity against human genes and path-
ways. Most of the ToxCast assays use human 
proteins and cells because our ultimate aim 
is to predict human toxicity. Assays probed 
231 human genes either through direct inter-
actions with the relevant protein or using a 
variety of indirect, downstream readouts of 
mRNA or protein levels. These genes were 
mapped to 143 published pathways from 
the KEGG (Kyoto Encyclopedia of Genes 
and Genomes) (Kanehisa et al. 2002) and 
Ingenuity Systems (http://www.  ingenuity.
com). From these human-based assays, com-
posite gene and pathway perturbation scores 
were calculated. We computed “gene per-
turbation scores” for the subset of genes for 
which we had one or more assays, and these 
were assigned an LEC value for each chem-
ical. The LEC is the minimum AC50/LEC 
value for that chemical in any assay that was 
mapped to that particular gene. We also com-
puted “pathway perturbation scores,” which 
were assigned the minimum AC50/LEC value 
for a chemical in any assay that was mapped 
to a gene in the pathway. For a chemical to 
be considered active in a pathway, it had to 
have shown activity in at least five assays that 
mapped to that pathway. A total of 122 path-
ways had at least one chemical hit. [The chem-
ical-by-pathway assay LEC values are given in 
Supplemental Material, Table 3 (doi:10.1289/
ehp.0901392).] This collection of published 
pathways show significant overlap, so we 
also compiled a minimal set of 33 pathways 
inclusive of all genes represented in the total 
pathway set. Although this is a small subset 
of the total number of human pathways that 
could lead to toxicity, it allows us to sample 
the range of potential activities across phase I 
chemicals. Supplemental Figure 2 shows a net-
work diagram of the minimal set of pathways 
linked to the genes for which we have assays. 
From this one can see redundancy between 
pathways in the down-selected target set.
Figure 2 shows the distribution of hits 
across all assays, direct assays, and gene and 
minimal pathway perturbation scores, as a 
function of the minimum AC50/LEC value 
used to define a hit. Direct assays are those 
measuring perturbation of chemical–target 
activity in an optimized biochemical assay 
(Table 1). The balance of the assays are cell 
based and mostly measure up- or down-
  regulation of particular genes or proteins 
through direct or indirect mechanisms of 
chemical activity. Because indirect effects can 
arise from multiple direct chemical–target 
interactions, chemicals logically show broader 
activity in these assays. The number of direct 
assay and total assay measurements for human 
targets are 130 and 425, respectively. In 
general, the ratio of hits between direct and 
indirect is much less than the overall ratio 
of the number of direct to indirect assays. 
Some chemicals show a large number of hits 
against direct targets. At a 30-µM cutoff for 
activity, nine chemicals have at least 20 direct 
hits: emamectin benzoate, fentin, imazalil, 
mancozeb, maneb, metiram-zinc, milbemec-
tin, oxytetracycline dihydrate, and PFOS. 
Mancozeb, maneb, and metiram-zinc are dif-
ferent salts of the same parent, and emamec-
tin benzoate and milbemectin are related 
macrocyclic antibiotics. Overall, however, 
these nine chemicals are structurally diverse. 
Figure 2B shows the same distribution of hits 
for the gene and minimal pathway assays. 
Note that the scale for the pathways is signifi-
cantly smaller because of the requirement that 
chemicals hit at least five pathway-mapped 
assays to be considered to have a positive 
pathway perturbation score. Except at the 
lowest cutoff of 1 µM, the median number of 
Figure 1. Heat map of 624 assay measurements (including multiple time points where available) in ToxCast 
phase I data set. Assays are arranged left to right, and chemicals are arranged top to bottom. The color 
bar at the top indicates the assay type: red (cell-free HTS), violet (multiplexed transcription reporter), yel-
low (biologically multiplexed activity profiling), green (high-content cell imaging), blue (multiplexed gene 
expression), pink (cell-based HTS), black (phase I and II XME cytotoxicity), white (real-time cell electronic 
sensing), and orange (HTS genotoxicity). Data values are –log10(AC50/LEC), where light pink is inactive and 
darker reds indicate increased activity (lower AC50/LEC).Judson et al.
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hits for genes or minimal pathways is > 5, and 
a number of chemicals show much broader 
activity than this. The chemicals that hit ≥ 20 
of the minimal pathways with a 30-µM cutoff 
are fluazinam, mancozeb, maneb, metiram-
zinc, and pyraclostrobin.
This broad range of activity is not seen 
universally across chemical classes. Figure 3 
shows the distribution of hits against the 
minimal pathway set with chemicals parsed 
by chemical class (limited to classes with at 
least 10 chemicals). The conazoles and tri-
azoles (many of which overlap) and pyre-
throids show the broadest activity spectrum, 
with median number of pathway hits of 
around 10 of the 33 minimal pathways. In 
contrast, the sulfonylurea and phenoxy com-
pounds are active in only a few pathways on 
average. However, even across the broadly 
active chemical classes, there is a spectrum of 
activity. These findings show that environ-
mental chemicals are active across multiple 
human genes and pathways.
We next examined the consequence of the 
multiplicity of pathways perturbed by these 
chemicals. A simple analysis is to see if the like-
lihood of cytotoxicity increases with the num-
ber of pathways in which a chemical is active. 
The data set includes 15 cytotoxicity assays 
using 11 primary human cell types or cell 
lines. We found a strong correlation between 
the number of pathways in which a chemical 
is called active and the minimum concentra-
tion at which cytotoxicity is observed across 
15 cytotoxicity assays. Figure 4 shows the cor-
relation between the number of pathway hits 
and the minimum AC50/LEC for cytotoxicity 
across the 15 assays. The p-value for the asso-
ciation is < 2.2E-16, and R2 = 0.55 for linear 
correlation.
We tested the hypothesis that the lower 
the concentrations at which a chemical shows 
activity in vitro, the lower will be the doses 
at which in vivo toxicity will be observed for 
that chemical. This hypothesis is based on 
three assumptions: a) Pathways perturbed by a 
chemical in vitro will also tend to be perturbed 
in vivo, although the magnitude may be very 
different because of tissue-specific feedback 
or adaptation not active in vitro. b) Pathway 
perturbations in vivo arising from specific 
chemical–target interactions require chemical 
concentration at the target site to be in the 
range where effects on the in vitro assay are 
seen; hence, lower in vitro AC50 values imply 
lower concentrations at which in vivo effects 
are seen. c) There are combinatorial pathways 
that, when perturbed, can lead to a given 
observed toxicity, and the AC50 values for the 
toxicity-related pathways for a chemical will be 
distributed randomly through the total distri-
bution of AC50 values, including some in the 
low concentration tail of that distribution.
To test this hypothesis, we first looked 
for direct correlations between low in vitro 
pathway perturbation score AC50 values for 
the minimal pathway set and the lowest dose 
at which toxicity was seen in vivo. Because we 
have only sparsely sampled the space of direct 
targets (e.g., enzymes, receptors), we used the 
number of pathways perturbed below some 
concentration threshold as a surrogate esti-
mate for minimum concentration at which a 
chemical significantly perturbs pathways. This 
is based on the assumption that each chemi-
cal shows a distribution of AC50 values across 
the complete set of pathways and that this 
distribution has a long tail going toward low 
concentrations. More pathway hits below a 
defined cutoff will correlate with the entire dis-
tribution shifting toward lower concentrations. 
For each chemical and each in vivo study type 
in ToxRefDB, we tabulated the lowest dose at 
which any treatment-related effect occurred. 
A linear regression fit between the number of 
pathway hits at concentrations < 30 µM (trend 
and significance is relatively insensitive to this 
cutoff) and the lowest dose at which toxic-
ity was observed yielded p-values of 0.0031 
(chronic rat), 0.0007 (chronic mouse), 0.037 
(developmental rat), 0.053 (developmental 
rabbit), and 0.019 (multigenerational rat). 
Except for the developmental rabbit study, all 
study types showed a significant association 
at the 0.05 level. In addition, the sign of the 
association was correct in all cases: The higher 
the number of low-concentration in vitro 
pathway hits, the lower the observed low-
est toxic dose in vivo. Therefore, these results 
show a significant association between low 
Figure 2. Distribution of number of hits per chemical as a function of AC50/LEC cutoff used to define a hit. 
(A) Distributions for all human assay measurements (out of 425) and the “direct” measurements from 
the cell-free HTS assays. The other assays are cell based and can potentially respond to multiple direct 
chemical interactions. (B) Number of hits per chemical for the gene and pathway perturbation scores. 
In each box and whisker plot, the heavy bar indicates the median, the boxes encompass the second and 
third quartiles, the whiskers extend to ±1.58 (interquartile range)/(number of assay-chemical hits), and the 
circles indicate outliers.
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in vitro concentrations for pathway perturba-
tions caused by a chemical and the lowest dose 
at which treatment-related effects are first seen 
in vivo.
We also performed the association calcula-
tion using the short-term half-maximal lethal 
dose (LD50) (International Programme on 
Chemical Safety 2005) as a covariate. LD50 
has a strong correlation with the lowest dose 
at which other toxic effect occurs and can help 
correct for factors not included in the path-
way parameter, including pharmacokinetics. 
In models including both terms, the p-values 
for association between the number of path-
way hits at concentrations < 30 µM and the 
lowest dose at which toxicity was observed 
were 0.0019 (chronic rat), 0.00015 (chronic 
mouse), 0.00049 (developmental rat), 0.011 
(developmental rabbit), and 0.00063 (multi-
generational rat). We see stronger correlations 
between in vitro activity and the threshold of 
toxicity after adjusting for LD50, and the sign 
of the effect was as hypothesized in all cases. 
The example in Figure 5 shows the results of 
the model fit for prenatal developmental toxic-
ity in rats, which resulted in the highest corre-
lation across the five study types (R2 = 0.51).
 Rat liver tumors and PPAR signaling. 
Almost half of the tested chemicals caused 
tumors in either rats or mice in high-dose 
2-year chronic/cancer bioassays (Martin 
et al. 2009a), with most of these having been 
determined by the U.S. EPA to be nongeno-
toxic tumorigens (U.S. EPA 2009). Of the 309 
chemicals tested, 248 have rat 2-year chronic/
cancer bioassay data entered into ToxRefDB, 
and 21 of these are liver tumorigens [chemi-
cals shown in Supplemental Material, Figure 3 
(doi:10.1289/ehp.0901392)]. These 21 are a 
subset of the 97 chemicals that are rat tum-
origens of any tissue type. All rat liver tumors 
caused by this set of chemicals were hepatocyte 
derived. We tested for univariate associations of 
all in vitro assays and gene perturbation scores 
against all rodent liver in vivo end points, and 
identified a total of five in vitro assays with a 
significant association with rat liver tumors 
(Fisher’s exact test p-value < 0.01). Results 
for these five assays and for the 21 chemicals 
that are rat liver tumorigens are illustrated in 
Supplemental Material, Figure 3. Three of the 
five assays are associated with the nuclear recep-
tor pathway genes PPARA and PPARG, one is 
associated with the cytokine chemokine (C-C 
motif) ligand 2 (CCL2), and the last with the 
AR. The PPARA transcription reporter assay 
shows high specificity (0.99) but low sensitiv-
ity (0.19) (Fisher’s exact p-value = 0.0005). 
The relative risk of causing rat liver tumors 
for chemicals being positive for this assay was 
9.5. The PPARG assay shows high sensitivity 
(0.86) but low specificity (0.53) (Fisher’s exact 
p-value = 0.0009). Also associated with rat liver 
proliferative lesions is hydroxymethylglutaryl-
coenzyme A synthase 2 (HMGCS2), which is 
a gene regulated by PPARA, providing indirect 
evidence that the human PPARα pathway has 
been activated by this group of chemicals.
PPAR activation is a well-studied mecha-
nism or mode of action for chemically induced 
liver tumors in rodents (Abbott 2008; Klaunig 
et al. 2003; Lai 2004; Peters 2008; Takeuchi 
et al. 2006). The primary role of PPARs is 
in lipid and fatty acid metabolism; however, 
xenobiotic compounds may activate PPAR in 
hepatocytes, leading to induction of xenobi-
otic metabolizing enzymes as well as peroxi-
some proliferation and hepatocyte hypertrophy. 
During prolonged exposure to PPAR activa-
tors, rodent hepatocytes can become hyperplas-
tic, necrotic, or apoptotic, and in some cases 
neoplastic. The relevance of PPAR-mediated 
rodent tumors to human toxicity and disease is 
an active area of research and debate (Desvergne 
et al. 2009; Guyton et al. 2009; Klaunig et al. 
2003). Nonetheless, based on the carcinogenic 
potential of PPAR-activating compounds, 
current U.S. Food and Drug Administration 
(FDA) guidance on PPAR agonists requires 
2-year carcinogenicity evaluations in rats and 
mice before initiation of human clinical studies 
longer than 6 months (U.S. FDA 2008).
CCL2 levels have been shown to be 
associated with severity or progression in a 
number of tumor types (Roca et al. 2008). 
CCL2 helps drive angiogenesis (Kuroda et al. 
Figure 4. Plot of the minimum concentration at which a chemical caused cyto-
toxicity as a function of the number of minimal pathways in which the chemical 
was active at concentrations < 30 µM. Chemicals for which no cytotoxicity was 
observed were assigned an AC50 of 1 mM. The correlation coefficient is mini-
mally sensitive to this default value. The line gives the fitted regression model. 
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2005). There is also evidence linking CCL2 
with up-regulation of bile acids, cholestatic 
liver injury, and fibrogenesis in rats (Ramm 
et al. 2009). Studies have discovered linkages 
between AR and androgen levels and hepato-
cellular carcinoma in humans and animals 
[reviewed by Kalra et al. (2008)].
There is extensive evidence that perturb-
ing androgen signaling activity is associated 
with increased risk of liver tumors. AR is 
expressed in the liver of rats (Konoplya and 
Popoff 1992) and humans (Iqbal et al. 1983), 
and hepatic tumor development is likely influ-
enced by androgens, as indicated by the fact 
that males have a greater prevalence of liver 
neoplasms in humans (Curado et al. 2007) 
and rodents (Kemp and Drinkwater 1989). 
Elevated levels of testosterone (Grange et al. 
1987) are associated with increased risk of 
hepatic adenomas in men. In male rats, testos-
terone (Morris and Firminger 1956) promote 
rat liver tumor development. The hypoth-
esized mode of action for the liver tumorige-
nicity of AR antagonists such as vinclozolin 
and linuron is as follows: The antiandrogens 
block AR function and negative feedback of 
the pituitary, so more luteinizing hormone 
is produced, which in turn leads to increased 
production of androgens by testicular Leydig 
cells. Whereas androgen homoeostasis may 
eventually reset, animals can have significantly 
elevated androgen levels, which can in turn 
promote liver tumor development.
We also investigated associations between 
in vitro assays and the progression of liver dis-
ease in rats. Chemicals were categorized accord-
ing to rat liver disease progression: those causing 
no liver lesions (122 chemicals) or causing any 
type of liver lesion (126 chemicals). Chemicals 
causing liver lesions could be classified further 
into subsets of those causing preneoplastic or 
neoplastic liver lesions (58 chemicals), or those 
causing just neoplastic liver lesions (21 chemi-
cals). All assays were correlated against these 
three rat liver lesion categories. Figure 6 shows 
associations with a p-value < 0.01 (either t-test 
or Fisher’s exact test), in which the genes linked 
to assays statistically associated with the three 
rat liver lesion categories, as well as human dis-
ease categories assigned through the Online 
Mendelian Inheritance in Man (OMIM) data-
base (Goh et al. 2007). PPARG, HMGCS2, 
and CCL2 are all associated with preneoplastic 
and neoplastic levels in the liver disease progres-
sion, and PPARA is additionally associated with 
neoplastic lesions.
More than half of genes with any associa-
tion were involved with xenobiotic metabo-
lism in the liver (9 of 15), with most of these 
being cytochrome P450 enzymes. Many of 
these XME genes are regulated by PPAR or 
other nuclear receptors, and other assays indi-
cated direct associations with rat and human 
pregnane X receptor (NR1I2). Preneoplastic 
and neoplastic liver lesions are also associated 
with PPARG activation. These data suggest that 
induction of liver neoplasms by these chemicals 
is PPARA dependent, and potentially coupled 
with PPARG and CCL2, whereas a variety of 
xenobiotic metabolism and other pathways can 
lead to more general liver lesions.
Discussion
The large ToxCast data set links in vitro 
and in vivo assay results to genes and path-
ways, providing a unique public resource for 
researchers modeling chemical biology and 
toxicity. We are expanding this collection in 
both chemical and assay space and plan to 
test thousands of environmental chemicals 
in the coming years. The examples we give 
here are among the many areas of toxicol-
ogy that can be explored using this data set, 
and we are finding other associations with 
chronic, developmental, and reproductive tox-
icity. In vitro assays directly probe chemical 
perturbations of pathways either by measur-
ing small molecule–protein interactions or 
closely linked downstream effects. Because 
of this, we can make use of information on 
links between genes, proteins, and diseases 
that have been derived from genetic variation 
and gene knockout studies. Organizing HTS 
in vitro data around human toxicity and dis-
ease pathways will allow synthesis with other 
mechanistic data on environmental chemi-
cals coming from genomics, proteomics, and 
metabolomics studies. An initial mapping of 
this set of assays to broad molecular, cellular, 
and disease classes using the OMIM-based 
categories of Goh et al. (2007) is illustrated in 
Supplemental Material, Figure 4 and Table 4 
(doi:10.1289/ehp.0901392). Genes in the 
current assay set are linked to various toxic-
ity end-point classes. One important series of 
next steps is to identify the key disease classes 
and pathways relevant to the toxicity of envi-
ronmental chemicals and to work with other 
researchers to develop critical missing assays in 
these pathways.
Our short-term goal is to screen large 
numbers of environmental chemicals and 
prioritize them for further testing, based on 
scores for disease-related predictive signatures 
and on exposure potential. The longer term 
goal is to use in vitro assays to understand 
the multitude of mechanisms of action for 
in vivo chemical toxicity, and for this to be 
realized there remain a number of significant 
challenges. The most widely held criticism of 
this in vitro–to–in vivo prediction approach 
is that genes or cells are not organisms and 
that the emergent properties of tissues and 
organisms are key determinants of whether 
Figure 6. Network of genes associated with the progression of rat liver tumor end points. Associations 
were calculated using Fisher’s exact test, with assay AC50/LEC values ≤ 100 µM set to 1 and those with 
> 100 µM set to 0. Only associations with a p-value < 0.01 are included. Links between genes (yellow) and 
in vivo end points (pink) are shown where there is a statistical association based on the in vitro assay 
results. The “Any lesion” category contains the “Preneoplastic” category, which in turn contains the 
“Neoplastic” lesions category. Disease or disorder classes (cyan) are linked to genes according to Goh 
et al. (2007).
Metabolic
Endocrine
NR112
AR
Cancer
CCL2
IL1A CXCL10
PLAT
THBD
Neoplastic Preneoplastic
Immunological
Cardiovascular
Hematological
Neurological
CYP2C19
CYP2C12
CYP2b1
CYP2a2
CYP3a4
Any lesion
PPARG PPARA HMGCS2ToxCast: in vitro screening of environmental chemicals
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 4 | April 2010  491
a particular chemical will be toxic. A related 
challenge is the understanding of what short-
timescale (hours to days) in vitro assays can tell 
us about long-timescale (months to years) pro-
cesses that lead to in vivo toxicity end points 
such as cancer. Finally, biotransformation of 
compounds into metabolites that can be more 
or less active than the parent clearly must be 
considered in the assay or modeling treatment. 
We either need assays in which realistic levels 
of biotransformation occur in vitro so that the 
complete suite of active metabolites can be 
assessed, or need to explicitly or implicitly test 
active metabolites.
Understanding the correlation between 
in vitro AC50/LEC values and the correspond-
ing chemical concentrations in blood or tissues 
will be crucial in extending this approach to 
quantitative risk assessments. If we find that 
environmental contaminants activate toxic-
ity pathways in cell systems at concentrations 
close to those detected in human samples, for 
instance, from population-wide biomonitor-
ing studies (Centers for Disease Control and 
Prevention 2005), it should raise the priority 
for studying the potential human toxicity of 
those chemicals (National Research Council 
2007). In ToxCast, we aim to predict the 
potential for chemicals to affect human health, 
but all of the current in vivo data being used 
to develop prediction models is from high-
dose animal testing. Where possible, it will be 
important to evaluate chemicals for which we 
have human toxicity data, such as pharma-
ceutical compounds that have displayed tox-
icities when tested in humans. The U.S. EPA 
and Pfizer Inc. have recently agreed to work 
together in testing such compounds in the next 
phases of ToxCast. Assuming these challenges 
are adequately addressed, we believe that this 
HTS approach for toxicity testing will be a 
practical solution for evaluating the backlog of 
thousands of untested environmental chemi-
cals, leading to more efficient, informed, and 
targeted testing for protection of public health.
Conclusions
The first phase of ToxCast, outlined here, 
is an important step in evaluating the use of 
high-throughput in vitro assays to prioritize 
chemicals for more detailed testing and to 
prioritize which tests should be run. The latter 
will be driven by the mechanistic understand-
ing that these assays provide. Perhaps the most 
important conclusion from the summary data 
presented here is how multifunctional these 
chemicals can be. Chemicals can hit many 
molecular targets and perturb many path-
ways, albeit typically with AC50 values of tens 
of micromolar. This means that understand-
ing the route from molecular interactions to 
in vivo toxicity will likely not be a matter of 
finding single molecular targets linked to well-
defined whole-animal phenotypes. Whether 
at the molecular, cellular, tissue, or whole-
  animal level, these chemicals have the poten-
tial to perturb many processes.
Understanding the complex biological 
cascades triggered by environmental chemi-
cals and understanding how to use in vitro 
data in a prioritization and regulatory con-
text will be complex tasks requiring insights 
spanning many disciplines. Because of the 
enormity of the challenge, we have already 
made the ToxCast phase I assay data avail-
able to a network of analysis partners around 
the world. These results are being compared 
with the $2 billion worth of traditional toxi-
cology results, collected by the U.S. EPA 
over the past 30 years and incorporated into 
ToxRefDB, as a transitional step toward a 
new toxicity testing paradigm focused on pre-
dicting the potential hazards of environmental 
chemicals. When key events are linked to tox-
icity and disease pathways, they provide regu-
latory agencies with a powerful new tool for 
determining under what conditions environ-
mental exposures pose risks to human health.
The ability to use molecular and computa-
tional sciences holds the potential to usher in 
a new era of prioritizing, assessing, and man-
aging chemicals at the U.S. EPA. Building 
this new toxicity testing paradigm will be a 
challenge and will take time, and no one orga-
nization can accomplish it alone. In addition, 
achieving these objectives will require trans-
parency, data sharing, peer review, and a cohe-
sive plan for interpretation and application of 
these emerging approaches. We are preparing 
to launch a second phase of ToxCast that 
will expand on and verify the ability of this 
approach to predict potential human toxicity. 
We expect to complete this second phase of 
ToxCast over the next several years and realize 
the promise of delivering innovative computa-
tional methods for evaluating potential health 
impacts of environmental chemicals.
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